|
1
|
Caplan AI: Adult mesenchymal stem cells
for tissue engineering versus regenerative medicine. J Cell
Physiol. 213:341–347. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu H, Qian H, Zhu W, Zhang X, Yan Y, Mao
F, Wang M, Xu H and Xu W: Mesenchymal stem cells relieve fibrosis
of Schistosoma japonicum-induced mouse liver injury. Exp Biol Med
(Maywood). 237:585–592. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Y, Qian H, Zhu W, Zhang X, Yan Y, Ye
S, Peng X, Li W and Xu W: Hepatocyte growth factor modification
promotes the amelioration effects of human umbilical cord
mesenchymal stem cells on rat acute kidney injury. Stem Cells Dev.
20:103–113. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dayan V, Yannarelli G, Billia F, Filomeno
P, Wang XH, Davies JE and Keating A: Mesenchymal stromal cells
mediate a switch to alternatively activated monocytes/macrophages
after acute myocardial infarction. Basic Res Cardiol.
106:1299–1310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu W, Qian H, Zhu W, Chen Y, Shao Q, Sun
X, Hu J, Han C and Zhang X: A novel tumor cell line cloned from
mutated human embryonic bone marrow mesenchymal stem cells. Oncol
Rep. 12:501–508. 2004.PubMed/NCBI
|
|
6
|
Esteller M: CpG island hypermethylation
and tumor suppressor genes: A booming present, a brighter future.
Oncogene. 21:5427–5440. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohta M, Inoue H, Cotticelli MG, Kastury K,
Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, et al:
The FHIT gene, spanning the chromosome 3p14.2 fragile site and
renal carcinoma-associated t(3;8) breakpoint, is abnormal in
digestive tract cancers. Cell. 84:587–597. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Connolly DC, Greenspan DL, Wu R, Ren X,
Dunn RL, Shah KV, Jones RW, Bosch FX, Muñoz N and Cho KR: Loss of
fhit expression in invasive cervical carcinomas and intraepithelial
lesions associated with invasive disease. Clin Cancer Res.
6:3505–3510. 2000.PubMed/NCBI
|
|
9
|
Guler G, Uner A, Guler N, Han SY,
Iliopoulos D, McCue P and Huebner K: Concordant loss of fragile
gene expression early in breast cancer development. Pathol Int.
55:471–478. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jeong YJ, Jeong HY, Lee SM, Bong JG, Park
SH and Oh HK: Promoter methylation status of the FHIT gene and Fhit
expression: Association with HER2/neu status in breast cancer
patients. Oncol Rep. 30:2270–2278. 2013.PubMed/NCBI
|
|
11
|
Sinha R, Hussain S, Mehrotra R, Kumar RS,
Kumar K, Pande P, Doval DC, Basir SF and Bharadwaj M: Kras gene
mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation:
Indicators of tumor staging and metastasis in adenocarcinomatous
sporadic colorectal cancer in Indian population. PLoS One.
8:e601422013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang JF, Zhang JG, Kuai XL, Zhang H,
Jiang W, Ding WF, Li ZL, Zhu HJ and Mao ZB: Reactivation of the
homeotic tumor suppressor gene CDX2 by
5-aza-2′-deoxycytidine-induced demethylation inhibits cell
proliferation and induces caspase-independent apoptosis in gastric
cancer cells. Exp Ther Med. 5:735–741. 2013.PubMed/NCBI
|
|
13
|
Kang HF, Dai ZJ, Bai HP, Lu WF, Ma XB, Bao
X, Lin S and Wang XJ: RUNX3 gene promoter demethylation by
5-Aza-CdR induces apoptosis in breast cancer MCF-7 cell line. Onco
Targets Ther. 6:411–417. 2013.PubMed/NCBI
|
|
14
|
Lin J, Yao DM, Qian J, Wang YL, Han LX,
Jiang YW, Fei X, Cen JN and Chen ZX: Methylation status of fragile
histidine triad (FHIT) gene and its clinical impact on prognosis of
patients with myelodysplastic syndrome. Leuk Res. 32:1541–1545.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cecener G, Tunca B, Egeli U, Bekar A,
Tezcan G, Erturk E, Bayram N and Tolunay S: The promoter
hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma.
Cell Mol Neurobiol. 32:237–244. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Griffiths EA, Gore SD, Hooker CM, Mohammad
HP, McDevitt MA, Smith BD, Karp JE, Herman JG and Carraway HE:
Epigenetic differences in cytogenetically normal versus abnormal
acute myeloid leukemia. Epigenetics. 5:590–600. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen X, Zhang H, Li P, Yang Z, Qin L and
Mo W: Gene expression of WWOX, FHIT and p73 in acute lymphoblastic
leukemia. Oncol Lett. 6:963–969. 2013.PubMed/NCBI
|
|
18
|
Karahoca M and Momparler RL:
Pharmacokinetic and pharmacodynamic analysis of
5-aza-2′-deoxycytidine (decitabine) in the design of its
dose-schedule for cancer therapy. Clin Epigenetics. 5:32013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sard L, Accornero P, Tornielli S, Delia D,
Bunone G, Campiglio M, Colombo MP, Gramegna M, Croce CM, et al: The
tumor-suppressor gene FHIT is involved in the regulation of
apoptosis and in cell cycle control. Proc Natl Acad Sci USA.
96:8489–8492. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alcazar O, Achberger S, Aldrich W, Hu Z,
Negrotto S, Saunthararajah Y and Triozzi P: Epigenetic regulation
by decitabine of melanoma differentiation in vitro and in vivo. Int
J Cancer. 131:18–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu X, Qian H, Zhu W, Zhang X, Yan Y, Wang
M and Xu W: Isolation of cancer stem cells from transformed human
mesenchymal stem cell line F6. J Mol Med Berl. 88:1181–1190. 2010.
View Article : Google Scholar : PubMed/NCBI
|
